Histopathologic evaluation of a new dermal allograft following explantation.
Numerous materials have been used to accomplish soft tissue augmentation, but the ideal implant remains elusive. Dermaplant is a recently introduced soft tissue matrix derived from human cadaveric dermis and intended for use in soft tissue reconstruction. This product is U.S. Food and Drug Administration (FDA) approved, but there is a paucity of data regarding its clinical performance. To report histopathologic findings of an explanted Dermaplant specimen. A healthy 52-year-old man underwent repair of postblepharoplasty eyelid retraction and a prominent tear trough defect. At the patient's request the tear trough implant was removed in the seventh postoperative week. Gross and microscopic evaluations were performed. Fibroblastic infiltration and new collagen production were demonstrated within the implant and at its periphery. Occasional macrophages and giant cells were also noted around the implant. In this patient the Dermaplant was well tolerated and supported ingrowth of host tissues. The behavior of this material over the long-term cannot be extrapolated from this study.